透明细胞脑膜瘤:35例罕见亚型的临床病理研究
本研究回顾性分析2003至2018年35例经组织学证实的颅内透明细胞脑膜瘤患者,平均年龄59.3岁,男女比例接近1:1。22例(62.9%)实现全切除,11例(31.4%)接受术后辅助放疗,17例(48.6%)复发,平均复发时间31.3个月。多因素分析显示全切除和辅助放疗均独立延长无进展生存期(P<0.033),但对总生存期无影响(P>0.274)。
要点
- 透明细胞脑膜瘤占所有脑膜瘤0.2%-0.8%,本组平均年龄59.3岁,男女比例近1:1。
- 全切除率62.9%,辅助放疗率31.4%,复发率48.6%,平均复发时间31.3个月。
- 全切除和辅助放疗独立延长无进展生存期(P<0.033),但不影响总生存期。
核心结论
- 全切除和术后辅助放疗均独立与更长的无进展生存期相关(P<0.033),但与总生存期无关(P>0.274)。
- 肿瘤复发仍是透明细胞脑膜瘤治疗中的挑战。
研究设计与样本
- 回顾性队列研究,纳入2003至2018年35例经组织学证实的颅内透明细胞脑膜瘤患者。
- 采用Kaplan-Meier和Cox比例风险分析比较总生存期和无进展生存期。
主要发现
- 35例患者中女性18例、男性17例,平均年龄59.3岁。
- 22例(62.9%)实现全切除,11例(31.4%)接受术后辅助放疗。
- 17例(48.6%)肿瘤复发,平均复发时间31.3个月,平均术后随访66.3个月。
关键数值与推荐
- 透明细胞脑膜瘤占所有脑膜瘤的0.2%-0.8%。
- 全切除和辅助放疗与延长无进展生存期独立相关(P<0.033),与总生存期无关(P>0.274)。
临床怎么用
- 对于透明细胞脑膜瘤,应争取全切除以延长无进展生存期。
- 术后辅助放疗可考虑用于延长无进展生存期,但需权衡其对总生存期无影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clear cell meningioma (CCM) is a rare histologic variant, accounting for only 0.2%-0.8% of all meningiomas. Given their relative infrequency, few cases have been reported. We have presented one of the largest series of patients with intracranial CCM and reported the treatments and outcomes of these patients. METHODS: Patients with histologically proven CCM from 2003 to 2018 were identified for inclusion in the present study. Relevant clinical and radiographic data were obtained via retrospective review and analyzed. Kaplan-Meier and Cox proportional hazards analyses were used to compare overall and progression-free survival. RESULTS: A total of 35 patients had undergone surgical resection for CCM, including 18 women and 17 men, with a mean age of 59.3 years. Gross total resection was achieved in 22 patients (62.9%), and 11 patients (31.4%) had received adjuvant postoperative radiotherapy. Tumors recurred in 17 patients (48.6%), with a mean time to recurrence of 31.3 months. The mean postoperative follow-up was 66.3 months. On multivariable analysis, adjuvant radiotherapy and gross total tumor resection were both independently associated with prolonged progression-free survival (P < 0.033), although not with overall survival (P >0.274). CONCLUSIONS: The data from the present series of 35 patients with CCM have shown distinct contrasts to previous series, with an older mean age and a nearly 1:1 male/female ratio. Although gross total resection and adjuvant postoperative radiotherapy were both independently associated with longer progression-free survival for patients with CCM, tumor recurrence has remained a challenge in the treatment of these patients.
引用
- Soni P, Li S, Sagar S, et al. Clear Cell Meningioma: A Clinicopathologic Study of a Rare Meningioma Subtype in 35 Patients. World Neurosurg. 2020. PMID: 32445901. doi:10.1016/j.wneu.2020.05.120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。